6 May 2020

Smith+Nephew receives Royal College of Surgeons accreditation for its new digital medical education programme

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, is pleased to announce that its new global digital medical education programme has been accredited by the Royal College of Surgeons of England.

Launched in March 2020 in response to the COVID-19 pandemic, the programme is designed to support the development of surgeons by providing educational webinars on the safe and effective use of Smith+Nephew products as well as surgical techniques.

Over the course of the initial month since launch, the programme has attracted healthcare professionals from more than 110 different countries, with attendance between 400 and 850 per event.  In total, more than 11,000 healthcare professionals have attended to hear from industry leading experts on a wide range of topics relevant to both our Orthopaedics and Sports Medicine Franchises.

Accreditation from the Royal College of Surgeons of England enables delegates to receive Continuing Professional Development (CPD) credit for each webinar they attend.

Cynthia Walker, Senior Vice President Medical Education at Smith+Nephew, said:

“To successfully provide our medical education programme online and be delivering courses regularly attended by thousands of surgeons in just a few weeks is an incredible achievement. Being endorsed by the Royal College of Surgeons of England is an important validation and we are grateful for their guidance and support.” 

This accreditation builds on the Royal College of Surgeons of England accreditation received in 2018 for Smith+Nephew’s surgical training facility, the Expert Connect Centre, in Watford, UK.





Charles Reynolds


+44 (0)7811 121398


Francesca Dunning


+44 (0)7583 003884




About Smith+Nephew

Smith+Nephew is a portfolio medical technology business that exists to restore people’s bodies and their self-belief by using technology to take the limits off living. We call this purpose ‘Life Unlimited’. Our 17,500+ employees deliver this mission every day, making a difference to patients’ lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global franchises of Orthopaedics, Advanced Wound Management and Sports Medicine & ENT.

Founded in Hull, UK, in 1856, we now operate in more than 100 countries, and generated annual sales of $5.1 billion in 2019. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms ‘Group’ and ‘Smith+Nephew’ are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.

For more information about Smith+Nephew, please visit www.smith-nephew.com and follow us on TwitterLinkedIn, Instagram or Facebook.


About the Royal College of Surgeons

The Royal College of Surgeons of England is a professional membership organisation and registered charity, which exists to advance surgical standards and improve patient care.

For more information, visit https://www.rcseng.ac.uk/ or to speak to a member of the Press Office, Telephone: 020 7869 6047/6052, or email: pressoffice@rcseng.ac.uk.


Forward-looking Statements

This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: risks related to the impact of COVID-19, such as the depth and longevity of its impact, government actions and other restrictive measures taken in response, material delays and cancelations of elective procedures, reduced procedure capacity at medical facilities, restricted access for sales representatives to medical facilities, or our ability to execute business continuity plans as a result of COVID-19; economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers (including, without limitation, as a result of COVID-19); price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers (including, without limitation, as a result of COVID-19); competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew's expectations


◊ Trademark of Smith+Nephew. Certain marks registered US Patent and Trademark Office.